APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaccine Conjugate

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vaccine Conjugate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025191 pages

Choose your research edition.

Industry ResearchVaccine Conjugate Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Conjugate Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Vaccine Conjugate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Conjugate Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Conjugate Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Vaccine Conjugate market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vaccine Conjugate include Bharat Biotech, Beijing Minhai Biotechnology, Beijing Xiangrui Biological Products, Chengdu Olymvax Biopharmaceuticals, GSK, Pfizer, CanSinoBIO, Royal (Wuxi) Bio-Pharmaceutical and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vaccine Conjugate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaccine Conjugate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine Conjugate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vaccine Conjugate market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaccine Conjugate Segment by Company

Bharat Biotech

Beijing Minhai Biotechnology

Beijing Xiangrui Biological Products

Chengdu Olymvax Biopharmaceuticals

GSK

Pfizer

CanSinoBIO

Royal (Wuxi) Bio-Pharmaceutical

Merck

Sanofi

Walvax Biotechnology

Zhifei Biologic

Vaccine Conjugate Segment by Type

Hib Vaccine

Pneumococcal Vaccine

Meningococcal Vaccine

Others

Vaccine Conjugate Segment by Application

Children

Adult

Vaccine Conjugate Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Conjugate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine Conjugate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Conjugate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vaccine Conjugate market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vaccine Conjugate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vaccine Conjugate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vaccine Conjugate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vaccine Conjugate Industry Trends Table 2. Vaccine Conjugate Industry Drivers Table 3. Vaccine Conjugate Industry Opportunities and Challenges Table 4. Vaccine Conjugate Industry Restraints Table 5. Global Vaccine Conjugate Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vaccine Conjugate Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vaccine Conjugate Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Vaccine Conjugate Sales Market Share by Manufacturers Table 9. Global Vaccine Conjugate Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vaccine Conjugate Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vaccine Conjugate Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vaccine Conjugate Manufacturers, Product Type & Application Table 13. Global Vaccine Conjugate Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vaccine Conjugate by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Hib Vaccine Table 17. Major Manufacturers of Pneumococcal Vaccine Table 18. Major Manufacturers of Meningococcal Vaccine Table 19. Major Manufacturers of Others Table 20. Global Vaccine Conjugate Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Vaccine Conjugate Sales by Type (2021-2026) & (K Units) Table 22. Global Vaccine Conjugate Sales by Type (2027-2032) & (K Units) Table 23. Global Vaccine Conjugate Sales Market Share by Type (2021-2026) Table 24. Global Vaccine Conjugate Sales Market Share by Type (2027-2032) Table 25. Global Vaccine Conjugate Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Vaccine Conjugate Revenue by Type (2021-2026) & (K Units) Table 27. Global Vaccine Conjugate Revenue by Type (2027-2032) & (K Units) Table 28. Global Vaccine Conjugate Revenue Market Share by Type (2021-2026) Table 29. Global Vaccine Conjugate Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Children Table 31. Major Manufacturers of Adult Table 32. Global Vaccine Conjugate Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Vaccine Conjugate Sales by Application (2021-2026) & (K Units) Table 34. Global Vaccine Conjugate Sales by Application (2027-2032) & (K Units) Table 35. Global Vaccine Conjugate Sales Market Share by Application (2021-2026) Table 36. Global Vaccine Conjugate Sales Market Share by Application (2027-2032) Table 37. Global Vaccine Conjugate Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Vaccine Conjugate Revenue by Application (2021-2026) & (K Units) Table 39. Global Vaccine Conjugate Revenue by Application (2027-2032) & (K Units) Table 40. Global Vaccine Conjugate Revenue Market Share by Application (2021-2026) Table 41. Global Vaccine Conjugate Revenue Market Share by Application (2027-2032) Table 42. Global Vaccine Conjugate Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Vaccine Conjugate Sales by Region (2021-2026) & (K Units) Table 44. Global Vaccine Conjugate Sales Market Share by Region (2021-2026) Table 45. Global Vaccine Conjugate Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Vaccine Conjugate Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Vaccine Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 49. North America Vaccine Conjugate Sales by Country (2027-2032) & (K Units) Table 50. Europe Vaccine Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 52. Europe Vaccine Conjugate Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Vaccine Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Vaccine Conjugate Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Vaccine Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Vaccine Conjugate Sales by Country (2027-2032) & (K Units) Table 59. Global Vaccine Conjugate Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Vaccine Conjugate Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Vaccine Conjugate Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Vaccine Conjugate Revenue Market Share by Region (2021-2026) Table 63. Global Vaccine Conjugate Revenue Market Share by Region (2027-2032) Table 64. Bharat Biotech Company Information Table 65. Bharat Biotech Business Overview Table 66. Bharat Biotech Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bharat Biotech Vaccine Conjugate Product Portfolio Table 68. Bharat Biotech Recent Development Table 69. Beijing Minhai Biotechnology Company Information Table 70. Beijing Minhai Biotechnology Business Overview Table 71. Beijing Minhai Biotechnology Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolio Table 73. Beijing Minhai Biotechnology Recent Development Table 74. Beijing Xiangrui Biological Products Company Information Table 75. Beijing Xiangrui Biological Products Business Overview Table 76. Beijing Xiangrui Biological Products Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolio Table 78. Beijing Xiangrui Biological Products Recent Development Table 79. Chengdu Olymvax Biopharmaceuticals Company Information Table 80. Chengdu Olymvax Biopharmaceuticals Business Overview Table 81. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolio Table 83. Chengdu Olymvax Biopharmaceuticals Recent Development Table 84. GSK Company Information Table 85. GSK Business Overview Table 86. GSK Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GSK Vaccine Conjugate Product Portfolio Table 88. GSK Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Pfizer Vaccine Conjugate Product Portfolio Table 93. Pfizer Recent Development Table 94. CanSinoBIO Company Information Table 95. CanSinoBIO Business Overview Table 96. CanSinoBIO Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. CanSinoBIO Vaccine Conjugate Product Portfolio Table 98. CanSinoBIO Recent Development Table 99. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 100. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 101. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolio Table 103. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 104. Merck Company Information Table 105. Merck Business Overview Table 106. Merck Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Merck Vaccine Conjugate Product Portfolio Table 108. Merck Recent Development Table 109. Sanofi Company Information Table 110. Sanofi Business Overview Table 111. Sanofi Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Sanofi Vaccine Conjugate Product Portfolio Table 113. Sanofi Recent Development Table 114. Walvax Biotechnology Company Information Table 115. Walvax Biotechnology Business Overview Table 116. Walvax Biotechnology Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Walvax Biotechnology Vaccine Conjugate Product Portfolio Table 118. Walvax Biotechnology Recent Development Table 119. Zhifei Biologic Company Information Table 120. Zhifei Biologic Business Overview Table 121. Zhifei Biologic Vaccine Conjugate Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Zhifei Biologic Vaccine Conjugate Product Portfolio Table 123. Zhifei Biologic Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Vaccine Conjugate Distributors List Table 127. Vaccine Conjugate Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Vaccine Conjugate Product Image Figure 2. Global Vaccine Conjugate Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Conjugate Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaccine Conjugate Sales (2021-2032) & (K Units) Figure 5. Global Vaccine Conjugate Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Vaccine Conjugate Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Hib Vaccine Image Figure 9. Pneumococcal Vaccine Image Figure 10. Meningococcal Vaccine Image Figure 11. Others Image Figure 12. Global Vaccine Conjugate Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Vaccine Conjugate Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Vaccine Conjugate Sales Market Share by Type (2021-2032) Figure 15. Global Vaccine Conjugate Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Vaccine Conjugate Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Vaccine Conjugate Revenue Market Share by Type (2021-2032) Figure 18. Children Image Figure 19. Adult Image Figure 20. Global Vaccine Conjugate Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Vaccine Conjugate Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Vaccine Conjugate Sales Market Share by Application (2021-2032) Figure 23. Global Vaccine Conjugate Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Vaccine Conjugate Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Vaccine Conjugate Revenue Market Share by Application (2021-2032) Figure 26. North America Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Vaccine Conjugate Sales Market Share by Country (2021-2032) Figure 28. U.S. Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Vaccine Conjugate Sales Market Share by Country (2021-2032) Figure 33. Germany Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Vaccine Conjugate Sales Market Share by Country (2021-2032) Figure 40. China Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Vaccine Conjugate Sales Market Share by Country (2021-2032) Figure 48. Brazil Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Vaccine Conjugate Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Vaccine Conjugate Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Vaccine Conjugate Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Vaccine Conjugate Revenue (2021-2032) & (US$ Million) Figure 59. North America Vaccine Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Vaccine Conjugate Revenue (2021-2032) & (US$ Million) Figure 61. Europe Vaccine Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Vaccine Conjugate Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Vaccine Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Vaccine Conjugate Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Vaccine Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Vaccine Conjugate Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Vaccine Conjugate Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Hib Vaccine
  • Pneumococcal Vaccine
  • Meningococcal Vaccine
  • Others
Applications
  • Children
  • Adult
Companies covered
  • Bharat Biotech
  • Beijing Minhai Biotechnology
  • Beijing Xiangrui Biological Products
  • Chengdu Olymvax Biopharmaceuticals
  • GSK
  • Pfizer
  • CanSinoBIO
  • Royal (Wuxi) Bio-Pharmaceutical
  • Merck
  • Sanofi
  • Walvax Biotechnology
  • Zhifei Biologic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vaccine Conjugate Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vaccine Conjugate Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vaccine Conjugate Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vaccine Conjugate Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vaccine Conjugate Market Dynamics
  1. 2.1 Vaccine Conjugate Industry Trends
  2. 2.2 Vaccine Conjugate Industry Drivers
  3. 2.3 Vaccine Conjugate Industry Opportunities and Challenges
  4. 2.4 Vaccine Conjugate Industry Restraints
3 Vaccine Conjugate Market by Manufacturers
  1. 3.1 Global Vaccine Conjugate Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vaccine Conjugate Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vaccine Conjugate Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vaccine Conjugate Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vaccine Conjugate Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vaccine Conjugate Manufacturers, Product Type & Application
  7. 3.7 Global Vaccine Conjugate Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vaccine Conjugate Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vaccine Conjugate Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vaccine Conjugate Tier 1, Tier 2, and Tier 3
4 Vaccine Conjugate Market by Type
  1. 4.1 Vaccine Conjugate Type Introduction
  2. 4.1.1 Hib Vaccine
  3. 4.1.2 Pneumococcal Vaccine
  4. 4.1.3 Meningococcal Vaccine
  5. 4.1.4 Others
  6. 4.2 Global Vaccine Conjugate Sales by Type
  7. 4.2.1 Global Vaccine Conjugate Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Vaccine Conjugate Sales by Type (2021-2032)
  9. 4.2.3 Global Vaccine Conjugate Sales Market Share by Type (2021-2032)
  10. 4.3 Global Vaccine Conjugate Revenue by Type
  11. 4.3.1 Global Vaccine Conjugate Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Vaccine Conjugate Revenue by Type (2021-2032)
  13. 4.3.3 Global Vaccine Conjugate Revenue Market Share by Type (2021-2032)
5 Vaccine Conjugate Market by Application
  1. 5.1 Vaccine Conjugate Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adult
  4. 5.2 Global Vaccine Conjugate Sales by Application
  5. 5.2.1 Global Vaccine Conjugate Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vaccine Conjugate Sales by Application (2021-2032)
  7. 5.2.3 Global Vaccine Conjugate Sales Market Share by Application (2021-2032)
  8. 5.3 Global Vaccine Conjugate Revenue by Application
  9. 5.3.1 Global Vaccine Conjugate Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Vaccine Conjugate Revenue by Application (2021-2032)
  11. 5.3.3 Global Vaccine Conjugate Revenue Market Share by Application (2021-2032)
6 Global Vaccine Conjugate Sales by Region
  1. 6.1 Global Vaccine Conjugate Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine Conjugate Sales by Region (2021-2032)
  3. 6.2.1 Global Vaccine Conjugate Sales by Region (2021-2026)
  4. 6.2.2 Global Vaccine Conjugate Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vaccine Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vaccine Conjugate Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vaccine Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vaccine Conjugate Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vaccine Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vaccine Conjugate Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vaccine Conjugate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vaccine Conjugate Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vaccine Conjugate Revenue by Region
  1. 7.1 Global Vaccine Conjugate Revenue by Region
  2. 7.1.1 Global Vaccine Conjugate Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vaccine Conjugate Revenue by Region (2021-2026)
  4. 7.1.3 Global Vaccine Conjugate Revenue by Region (2027-2032)
  5. 7.1.4 Global Vaccine Conjugate Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vaccine Conjugate Revenue (2021-2032)
  8. 7.2.2 North America Vaccine Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vaccine Conjugate Revenue (2021-2032)
  11. 7.3.2 Europe Vaccine Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vaccine Conjugate Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vaccine Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vaccine Conjugate Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vaccine Conjugate Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bharat Biotech
  2. 8.1.1 Bharat Biotech Company Information
  3. 8.1.2 Bharat Biotech Business Overview
  4. 8.1.3 Bharat Biotech Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bharat Biotech Vaccine Conjugate Product Portfolio
  6. 8.1.5 Bharat Biotech Recent Developments
  7. 8.2 Beijing Minhai Biotechnology
  8. 8.2.1 Beijing Minhai Biotechnology Company Information
  9. 8.2.2 Beijing Minhai Biotechnology Business Overview
  10. 8.2.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolio
  12. 8.2.5 Beijing Minhai Biotechnology Recent Developments
  13. 8.3 Beijing Xiangrui Biological Products
  14. 8.3.1 Beijing Xiangrui Biological Products Company Information
  15. 8.3.2 Beijing Xiangrui Biological Products Business Overview
  16. 8.3.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolio
  18. 8.3.5 Beijing Xiangrui Biological Products Recent Developments
  19. 8.4 Chengdu Olymvax Biopharmaceuticals
  20. 8.4.1 Chengdu Olymvax Biopharmaceuticals Company Information
  21. 8.4.2 Chengdu Olymvax Biopharmaceuticals Business Overview
  22. 8.4.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolio
  24. 8.4.5 Chengdu Olymvax Biopharmaceuticals Recent Developments
  25. 8.5 GSK
  26. 8.5.1 GSK Company Information
  27. 8.5.2 GSK Business Overview
  28. 8.5.3 GSK Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GSK Vaccine Conjugate Product Portfolio
  30. 8.5.5 GSK Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Vaccine Conjugate Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 CanSinoBIO
  38. 8.7.1 CanSinoBIO Company Information
  39. 8.7.2 CanSinoBIO Business Overview
  40. 8.7.3 CanSinoBIO Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CanSinoBIO Vaccine Conjugate Product Portfolio
  42. 8.7.5 CanSinoBIO Recent Developments
  43. 8.8 Royal (Wuxi) Bio-Pharmaceutical
  44. 8.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  45. 8.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  46. 8.8.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolio
  48. 8.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  49. 8.9 Merck
  50. 8.9.1 Merck Company Information
  51. 8.9.2 Merck Business Overview
  52. 8.9.3 Merck Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck Vaccine Conjugate Product Portfolio
  54. 8.9.5 Merck Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Vaccine Conjugate Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Walvax Biotechnology
  62. 8.11.1 Walvax Biotechnology Company Information
  63. 8.11.2 Walvax Biotechnology Business Overview
  64. 8.11.3 Walvax Biotechnology Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Walvax Biotechnology Vaccine Conjugate Product Portfolio
  66. 8.11.5 Walvax Biotechnology Recent Developments
  67. 8.12 Zhifei Biologic
  68. 8.12.1 Zhifei Biologic Company Information
  69. 8.12.2 Zhifei Biologic Business Overview
  70. 8.12.3 Zhifei Biologic Vaccine Conjugate Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zhifei Biologic Vaccine Conjugate Product Portfolio
  72. 8.12.5 Zhifei Biologic Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vaccine Conjugate Value Chain Analysis
  2. 9.1.1 Vaccine Conjugate Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vaccine Conjugate Production Mode & Process
  6. 9.2 Vaccine Conjugate Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vaccine Conjugate Distributors
  9. 9.2.3 Vaccine Conjugate Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst